Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 15/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.70 |
| ▸ | NCOR2 | Q9Y618 | 11/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.62 |
| ▸ | TET3 | O43151 | 1/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.62 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.62 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.62 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.62 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3261132 | 1.00 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL20838340 | 0.88 | HDAC1 (0.62) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL20165848 | 0.82 | HDAC1 (0.61) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL4380122 | 0.82 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL4380126 | 0.82 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL29454794 | 0.82 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL12487265 | 0.82 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL3261129 | 0.82 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL164803 | 0.82 | HDAC1 (0.73) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL23511025 | 0.81 | HDAC1 (0.72) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032532-A2 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-Ý4-ÝÝÝ2-(2-METHYL-1H-INDOL-3-YL)ETHYL¨AMINO¨METHYL¨PHENYL¨-2E-2-PROPENAMIDE | Novartis AG (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-2032533-A2 | PROCESS FOR MAKING N-HYDROXY-3-Ý4-ÝÝÝ2-(2-METHYL-1H-INDOL-3-YL)ETHYL¨AMINO¨METHYL¨PHENYL¨-2E-2-PROPENAMIDE AND STARTING MATERIALS THEREFOR | Novartis AG (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-2004234-A2 | COMBINATION OF ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007146717-A2 | PROCESS FOR MAKING SALTS OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENAMIDE | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | claimed |
| WO-2007146718-A2 | PROCESS FOR MAKING N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO] METHYL]PHENYL]-2E-2-PROPENAMIDE AND STARTING MATERIALS THEREFOR | NOVARTIS AG (CH) | 2007-12-21 | — | — | WO | claimed |
| WO-2007115287-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| EP-4281463-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN Pharmaceutica NV (BE) | 2023-11-29 | — | — | EP | disclosed |
| WO-2021113665-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| EP-3046563-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015042077-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2611436-A1 | COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS | Novartis AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| CN-103086944-A | Process for making n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide and starting materials therefor | NOVARTIS AG | 2013-05-08 | — | — | CN | disclosed |
| WO-2012030886-A1 | COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS | NOVARTIS AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| EP-1628651-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | Novartis AG (CH) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005013958-A1 | HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004103358-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | disclosed |
| EP-1443967-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | Novartis AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003039599-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |